Lymphoma  >>  dexamethasone  >>  Phase 1
Welcome,         Profile    Billing    Logout  

22 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT02518113 / 2006-005313-35: A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Completed
1b
36
Europe, US, RoW
LY3039478, Dexamethasone, Placebo
Eli Lilly and Company
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
01/18
01/18
NCT00000689 / 2011-003233-34: Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Completed
1
18
US
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Non-Hodgkin, HIV Infections
 
03/91
NCT00060684: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Completed
1
30
US
Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab
CTI BioPharma
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
01/05
05/07
NCT00150462: Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Completed
1
48
US
Carfilzomib, PR-171, Kyprolis, Dexamethasone
Amgen
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
10/09
10/09
NCT00608907: An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Completed
1
61
Europe, RoW
bortezomib, VELCADE, bortezomib, rifampicin, rifampicin, bortezomib, dexamethasone, dexamethasone
Millennium Pharmaceuticals, Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Multiple Myeloma, Non-Hodgkin's Lymphoma
03/10
04/10
NCT01534949: Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial

Terminated
1
1
RoW
rituximab
Celltrion
Diffuse Large B-Cell Lymphoma
02/13
02/13
NCT01055496: Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1 data
Nov 2012 - Nov 2012: P1 data
Checkmark P1 interim data in NHL
More
Completed
1
103
Europe, Canada, Japan, US, RoW
inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, CMC-544, inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Pfizer, UCB Pharma
Lymphoma, B-Cell
07/13
03/14
NCT00598169: Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Completed
1
23
US
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC
Lymphoma
10/14
11/14
NCT02071888: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Completed
1
25
US
CB-839, CB-839 and low dose dexamethasone, CBd, CB-839, pomalidomide, and low dose dexamethasone, CBPd
Calithera Biosciences, Inc
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
04/16
04/16
NCT01846390: Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Completed
1
21
Canada
Gemcitabine, Dexamethasone, Cisplatin, Romidepsin
Canadian Cancer Trials Group, Celgene
Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
07/16
09/18
NCT02223598: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

Terminated
1
120
US, Canada
CB-5083, Dexamethasone
Cleave Biosciences, Inc.
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
07/17
07/17
NCT03465540: Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Terminated
1
24
Europe, Japan, US, RoW
AMG 397, Dexamethasone, Azacitidine
Amgen
Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
07/19
07/19
KPT-330+RICE, NCT02471911: KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Completed
1
22
US
KPT-330, Selinexor, Rituximab, Rituxan, Etoposide, Carboplatin, Ifosfamide, Dexamethasone
Weill Medical College of Cornell University, Karyopharm Therapeutics Inc, The Leukemia and Lymphoma Society, FDA Office of Orphan Products Development
Diffuse Large B-Cell Lymphoma
10/19
10/21
NCT03795571: Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Unknown status
1
12
RoW
Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone, Lenalidomide Oral Capsule
The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
12/19
12/19
SELINDA, NCT02741388: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Completed
1
39
Europe
selinexor, KPT-330, Rituximab, Dexamethasone, Oxaliplatin, Cisplatin, Cytarabine, Gemcitabine
The Lymphoma Academic Research Organisation, Karyopharm Therapeutics Inc
B-cell Lymphoma
09/21
09/21
NCT04818372: Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Recruiting
1
87
RoW
CM313-Dose escalation, CM313, Dexamethasone, Lenalidomide
Keymed Biosciences Co.Ltd
Multiple Myeloma, Lymphoma
01/23
04/23
NCT04514029: Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Active, not recruiting
1
37
US
Simvastatin, Dexamethasone
Masonic Cancer Center, University of Minnesota
Lymphoma
11/23
12/25
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
NCT02203526: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Recruiting
1
93
US
Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2, 3 and 4), Methotrexate, Ibrutinib (Arm 1 - Closed with Amendment G), Ibrutinib (Arm 4)
National Cancer Institute (NCI)
Primary Central Nervous System Lymphoma
06/25
06/27
NCT04447027: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Active, not recruiting
1
20
US
Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone
National Cancer Institute (NCI)
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
11/24
05/25
NCT03719105: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Recruiting
1
40
US
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
New York Medical College, University of Alabama at Birmingham
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
12/25
12/26
NCT05688475: A Rollover Study of CC-122

Active, not recruiting
1
12
Europe, Japan, US
CC-122, Avadomide, BMS-986381, Dexamethasone
Bristol-Myers Squibb
Non-Hodgkin Lymphoma
02/26
02/26

Download Options